Inovio Pharmaceuticals

Inovio Pharmaceuticals is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Company Growth (employees)
Type
Public
HQ
Blue Bell, US
Founded
1979
Size (employees)
239 (est)
Website
inovio.com
Inovio Pharmaceuticals was founded in 1979 and is headquartered in Blue Bell, US

Key People/Management at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim

CEO
Peter Kies

Peter Kies

CFO
Niranjan Sardesai

Niranjan Sardesai

COO
Mark Bagarazzi

Mark Bagarazzi

Chief Medical Officer

Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has offices in Blue Bell and San Diego
Blue Bell, US (HQ)
1787 Sentry Parkway West
San Diego, US
6769 Mesa Ridge Rd
San Diego, US
10480 Wateridge Cir
Show all (3)

Inovio Pharmaceuticals Financials and Metrics

Inovio Pharmaceuticals Financials

Inovio Pharmaceuticals's revenue was reported to be $8.5 m in FY, 2016
USD

Revenue (Q2, 2017)

20.4 m

EBIT (Q2, 2017)

(9.6 m)

Market capitalization (22-Dec-2017)

376.2 m

Cash (30-Jun-2017)

23.9 m
Inovio Pharmaceuticals's current market capitalization is $376.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

13.5 m10.5 m40.6 m8.5 m

Revenue growth, %

(22%)288%(79%)

EBIT

(19.5 m)(39.5 m)(34.3 m)(22.4 m)

EBIT margin, %

(145%)(378%)(85%)(263%)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

9.5 m2.4 m3.8 m1.8 m5.2 m5.3 m24.2 m8.1 m6.2 m12.5 m10.4 m20.4 m

R&D expense

5.4 m8.2 m9.6 m7 m9.4 m16.7 m16.1 m18.2 m19.6 m27 m24.5 m23.9 m

General and administrative expense

3.3 m4.1 m4.3 m3.2 m4.1 m4.7 m4.4 m5.4 m5.8 m5.8 m7.8 m6.2 m

Operating expense total

8.7 m12.4 m14 m10.2 m13.5 m20.4 m20.5 m23.6 m24.4 m32.7 m32.3 m30 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33.7 m40.5 m57.6 m19.1 m

Accounts Receivable

3.3 m2.8 m7.3 m15.8 m

Inventories

637.4 k798 k917.3 k1.7 m

Current Assets

58.7 m98.9 m171.9 m124.6 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

33.1 m98.8 m88.5 m70.7 m26.1 m70.3 m85.5 m41.6 m28.5 m23.3 m22.9 m23.9 m

Accounts Receivable

10.6 m2.7 m2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m7.5 m

Current Assets

57.9 m121.7 m112.9 m104.6 m87.3 m162.1 m184.1 m160.6 m148 m140.2 m106.8 m106.9 m

Goodwill

10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.5 m10.5 m10.5 m10.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)

Depreciation and Amortization

2.1 m1.6 m1.9 m3.1 m

Accounts Receivable

(2.5 m)499.2 k(4.5 m)(8.5 m)

Inventories

(229.7 k)(160.5 k)(119.3 k)(831.8 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(30.9 m)(10.8 m)(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)

Accounts Receivable

2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m

Accounts Payable

5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m
Y, 2017

Financial Leverage

1.3 x
Show all financial metrics

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

620
Show all operating metrics

Inovio Pharmaceuticals Market Value History

Inovio Pharmaceuticals's Web-traffic and Trends

Inovio Pharmaceuticals Online and Social Media Presence

Inovio Pharmaceuticals Company Life and Culture

You may also be interested in